Readers share their opinions on some of the most talked-about breast cancer abstracts they’re looking forward to seeing at ESMO 2026.
Commentary|Videos|December 13, 2024
Dr Grinshpun on Ultra-Sensitive ctDNA Detection in HR+ Early Breast Cancer
Author(s)Albert Grinshpun, MD, MSc
Fact checked by: Ashling Wahner , Chris Ryan
Albert Grinshpun, MD, MSc, discusses the utility of ctDNA as a predictive biomarker of endocrine therapy sensitivity in patients with HR+ breast cancer.
Advertisement
Albert Grinshpun, MD, MSc, head, Breast Oncology Service, Shaare Zedek Medical Center, discusses a study evaluating the potential utility of circulating tumor DNA (ctDNA) as a predictive biomarker of endocrine therapy sensitivity in patients with hormone receptor (HR)–positive early breast cancer.
Advertisement
Related to this article
The 510(k) clearance covers an MRI-derived AI risk score for stage I to IIIA disease; the high-risk category carried an HR of 2.81 for recurrence.
The top 5 OncLive TV videos of the week cover insights in multiple myeloma, HR+ breast cancer, CAR T-cell therapy, CLL, and oral SERDs.
Experts spotlight the prostate and bladder cancer presentations they're most excited to see at the 2026 ESMO Congress.
Nunnery and Bond discuss how patients and advocates can navigate second opinions, mental health support, and the long-term effects of cancer treatment.
Read on to see which data are poised to shape clinical discussions and decision-making in lung cancer at the 2026 ESMO Congress in Madrid, Spain.
Invikafusp alfa now holds fast track status across TMB-H solid tumors that progressed after prior therapy, including checkpoint inhibition.
Experts in gynecologic oncology overview top research being presented at the 2026 ESMO Congress.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Dostarlimab for dMMR/MSI-H Locally Advanced Rectal Cancer
2
VOLGA, DASL-HiCaP Data Highlight Key Genitourinary Cancer Presentations Arriving at ESMO 2026
3
Five Under 5: Top Oncology Videos for the Week of 10/12
4
Early-Phase INCA33890 Data Lay the Foundation for Phase 3 Combination Research in MSS CRC
5